2008•CytotherapyRequires access

Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy

Keith Wonnacott, D. Lavoie, Robert P. Fiorentino, M. McIntyre, Ying Huang, Steven Hirschfeld

Open publisher page 13 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 13 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Food and drug administration, Medicine, Clinical research, Drug, Clinical trial, Genetic enhancement, New drug application, Clinical pharmacology

Back to paper search Browse research topics Original source

Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy — Research Paper | ScholarLens